IDRx is a clinical-stage biopharmaceutical company focused on precision therapies for cancer, with its lead program IDRX-42, a potent oral, highly selective KIT inhibitor for KIT-mutant GIST. The company presented preliminary Phase 1 data at ASCO showing a 23% ORR across all patients (median four prior lines of therapy) and a 43% ORR in second-line patients, with a favorable tolerability profile. IDRX-42 targets major activating and resistance KIT mutations and has shown superior preclinical antitumor activity versus imatinib and sunitinib in xenograft models. The FDA has granted Fast Track designation to IDRX-42 for GIST after progression on or intolerance to imatinib. IDRx plans to use the financing to support the ongoing Phase 1/1b StrateGIST 1 study and to fund the expected initiation of the first pivotal study in second-line GIST. The company was founded in 2021 and is based in Plymouth, Massachusetts. IDRx is a clinical-stage biopharmaceutical company building intentionally designed precision combination therapies to address tumor escape mechanisms and extend durable responses. The company was incubated by Borisy Labs and launched with a $122 million oversubscribed Series A. Its pipeline includes small-molecule tyrosine kinase inhibitors IDRX-42 and IDRX-73, acquired via license agreements with Merck KGaA and Blueprint Medicines, respectively. A Phase 1 first-in-human study of IDRX-42 has been initiated, and IDRX-73 is advancing toward the clinic; IDRX-42 has FDA Orphan Drug designation for GIST. IDRx is initially focusing on non-PDGFR-driven gastrointestinal stromal tumor (GIST) where there is significant unmet need. The leadership and founders include experienced drug developers and clinicians involved in the discovery, development and commercialization of more than 10 approved drugs. The company was founded in 2021 and is based in Plymouth, Mass.

Total raised

$242M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2024